Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Kidney360 ; 2(12): 1945-1952, 2021 12 30.
Article in English | MEDLINE | ID: mdl-35419530

ABSTRACT

Background: Hemodialysis arteriovenous fistulas (AVFs) are the preferred vascular access for patients on hemodialysis. In the Hemodialysis Fistula Maturation Study, 44% of the patients achieved unassisted maturation of their fistula without needing an intervention. Venous neointimal hyperplasia (VNH) and subsequent venous stenosis are responsible for lack of maturation. There are no therapies that can prevent VNH/VS formation. The goal of this paper is to present the background, rationale, and trial design of an innovative phase 1/2 clinical study that is investigating the safety of autologous adipose-derived mesenchymal stem cells delivered locally to the adventitia of newly created upper extremity radiocephalic (RCF) or brachiocephalic fistula (BCF). Methods: The rationale and preclinical studies used to obtain a physician-sponsored investigational new drug trial are discussed. The trial design and end points are discussed. Results: This is an ongoing trial that will complete this year. Conclusion: This is a phase 1/2 single-center, randomized trial that will investigate the safety and efficacy of autologous AMSCs in promoting maturation in new upper-extremity AVFs.Clinical Trial registration number: NCT02808208.


Subject(s)
Arteriovenous Fistula , Arteriovenous Shunt, Surgical , Mesenchymal Stem Cells , Renal Dialysis , Arteriovenous Fistula/etiology , Arteriovenous Fistula/prevention & control , Arteriovenous Shunt, Surgical/adverse effects , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Constriction, Pathologic/etiology , Constriction, Pathologic/prevention & control , Humans , Neointima , Randomized Controlled Trials as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...